Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters - Tostanoski, Lisa H.; Wegmann, Frank; Martinot, Amanda J.; Loos, Carolin; McMahan, Katherine; Mercado, Noe B.; Yu, Jingyou; Chan, Chi N.; Bondoc, Stephen; Starke, Carly E.; Nekorchuk, Michael; Busman-Sahay, Kathleen; et al. (Nature medicine, 2020)
Keywords: 631/326/590; 631/326/596/4130; Adenoviridae - genetics; Adenoviridae - immunology; Adenoviruses; Animals; Antibodies; Antibodies, Neutralizing - genetics; Antibodies, Neutralizing - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cancer Research; Coronaviruses; COVID-19; COVID-19 - mortality; COVID-19 - pathology; COVID-19 - prevention & control; COVID-19 - virology; COVID-19 Vaccines - genetics; COVID-19 Vaccines - therapeutic use; Cricetinae; Disease Models, Animal; Female; Genetic Vectors; Hamsters; Humans; Immunization; Infectious Diseases; Letter; Male; Mesocricetus; Metabolic Diseases; Molecular Medicine; Mortality; Neurosciences; Pathogenesis; Pneumonia; Proteins; Replication; Respiratory diseases; Respiratory failure; Respiratory tract; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Severity of Illness Index; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; Spike protein; Vaccines; Vaccines, Synthetic - genetics; Vaccines, Synthetic - therapeutic use; Viral diseases; Viral Load; Weight loss; United States